Hanmi Pharm jumps into an approx. KRW 140 billion market of chronic hepatitis B treaments
Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) will jump into the market of chronic hepatitis B treatments containing tenofovir, which forms a market of approximately KRW 140 billion a year.
After acquiring commercialization approval of ‘Tefovir Tab,’ a hepatitis B treatment, from the Ministry of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
